42 results on '"Svetlovska D"'
Search Results
2. Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial
- Author
-
Mego, M., Svetlovska, D., Reckova, M., Angelis, De, Kalavska, K., Obertova, J., Palacka, P., Rejlekova, K., Sycova-Mila, Z., Chovanec, M., and Mardiak, J.
- Published
- 2021
- Full Text
- View/download PDF
3. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer
- Author
-
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., and Mardiak, J.
- Published
- 2019
- Full Text
- View/download PDF
4. Long-term sexual functioning in germ-cell tumor survivors
- Author
-
Chovanec, M., Vasilkova, L., Petrikova, L., Obertova, J., Palacka, P., Rejlekova, K., Sycova-Mila, Z., Kalavska, K., Svetlovska, D., Mladosievicova, B., Mardiak, J., and Mego, M.
- Published
- 2020
- Full Text
- View/download PDF
5. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
- Author
-
Cierna, Z., Mego, M., Miskovska, V., Machalekova, K., Chovanec, M., Svetlovska, D., Hainova, K., Rejlekova, K., Macak, D., Spanik, S., Ondrus, D., Kajo, K., Mardiak, J., and Babal, P.
- Published
- 2016
- Full Text
- View/download PDF
6. 786P A phase II trial of paclitaxel, ifosfamid and cisplatin in patients with poor-prognosis disseminated non-seminomatous germ cell tumors with unfavorable serum tumor marker decline after first cycle of chemotherapy
- Author
-
Mego, M., primary, Svetlovska, D., additional, Rejlekova, K., additional, Miskovska, V., additional, De Angelis, V., additional, Kalavska, K., additional, Obertova, J., additional, Palacka, P., additional, Sycova-Mila, Z., additional, Chovanec, M., additional, and Mardiak, J., additional
- Published
- 2020
- Full Text
- View/download PDF
7. The prognostic value of DNA damage level in peripheral blood lymphocytes in germ cell cancer patients
- Author
-
Mego, M., primary, Sestakova, Z., additional, Kalavska, K., additional, Hurbanova, L., additional, Jurkovicova, D., additional, Gursky, J., additional, Chovanec, M., additional, Svetlovska, D., additional, Miskovska, V., additional, Obertova, J., additional, Palacka, P., additional, Rejlekova, K., additional, Sycova-Mila, Z., additional, and Mardiak, J., additional
- Published
- 2018
- Full Text
- View/download PDF
8. Survival is associated with circulating cytokine levels in metastatic testicular germ cell tumors
- Author
-
Svetlovska, D., primary, Miskovska, V., additional, Cholujova, D., additional, Gronesova, P., additional, Cingelova, S., additional, Chovanec, M., additional, Sycova-Mila, Z., additional, Obertova, J., additional, Palacka, P., additional, Rajec, J., additional, Kalavska, K., additional, Usakova, V., additional, Luha, J., additional, Ondrus, D., additional, Spanik, S., additional, Mardiak, J., additional, and Mego, M., additional
- Published
- 2016
- Full Text
- View/download PDF
9. 913P - The prognostic value of DNA damage level in peripheral blood lymphocytes in germ cell cancer patients
- Author
-
Mego, M., Sestakova, Z., Kalavska, K., Hurbanova, L., Jurkovicova, D., Gursky, J., Chovanec, M., Svetlovska, D., Miskovska, V., Obertova, J., Palacka, P., Rejlekova, K., Sycova-Mila, Z., and Mardiak, J.
- Published
- 2018
- Full Text
- View/download PDF
10. Fibrillin-1 (FBN-1) a new marker of germ cell neoplasia in situ
- Author
-
Cierna, Z., primary, Mego, M., additional, Jurisica, I., additional, Machalekova, K., additional, Chovanec, M., additional, Miskovska, V., additional, Svetlovska, D., additional, Kalavska, K., additional, Rejlekova, K., additional, Kajo, K., additional, Mardiak, J., additional, and Babal, P., additional
- Published
- 2016
- Full Text
- View/download PDF
11. 1561P - Survival is associated with circulating cytokine levels in metastatic testicular germ cell tumors
- Author
-
Svetlovska, D., Miskovska, V., Cholujova, D., Gronesova, P., Cingelova, S., Chovanec, M., Sycova-Mila, Z., Obertova, J., Palacka, P., Rajec, J., Kalavska, K., Usakova, V., Luha, J., Ondrus, D., Spanik, S., Mardiak, J., and Mego, M.
- Published
- 2016
- Full Text
- View/download PDF
12. Effects of novel stressors on plasma catecholamine levels in rats exposed to long-term cold
- Author
-
Dronjak, Slađana, Ondriska, M, Svetlovska, D, Jezova, D, and Kvetnansky, R
- Subjects
education ,reproductive and urinary physiology ,health care economics and organizations ,humanities - Abstract
7th Symposium on Catecholamines and Other Neurotransmitters in Stress, Jun 28-Jul 03, 1999, Smolenice Castle, Slovakia
- Published
- 2002
13. Phase II Study of Everolimus (E) in Refractory Germ Cell Tumors (GCTS)
- Author
-
Reckova, M., primary, Mego, M., additional, Svetlovska, D., additional, Miskovska', V., additional, Obertova, J., additional, Sycova-Mila, Z., additional, Palacka, P., additional, Rajec, J., additional, Liskova, S., additional, and Mardiak, J., additional
- Published
- 2012
- Full Text
- View/download PDF
14. Phase II study of sunitinib malate in refractory germ cell tumors.
- Author
-
Reckova, M., primary, Mego, M., additional, Sycova-Mila, Z., additional, Obertova, J., additional, Svetlovska, D., additional, and Mardiak, J., additional
- Published
- 2011
- Full Text
- View/download PDF
15. Gemcitabine and carboplatin treatment in Patients with relapsing ovarian cancer
- Author
-
SUFLIARSKY, J., primary, CHOVANEC, J., additional, SVETLOVSKA, D., additional, MINARIK, T., additional, PACKAN, T., additional, KROSLAKOVA, D., additional, LALABOVA, R., additional, HELPIANSKA, L., additional, HORVATHOVA, D., additional, SEVCIK, L., additional, SPACEK, J., additional, LALUHA, A., additional, TKACOVA, V., additional, MALEC, V., additional, RAKICKA, G., additional, MAGDIN, D., additional, JANCOKOVA, I., additional, DORR, A., additional, STRESKO, M., additional, HABETINEK,, V., additional, and Koza, I., additional
- Published
- 2009
- Full Text
- View/download PDF
16. The beneficial effect of probiotics in the prevention of irinotecan-induced diarrhea in colorectal cancer patients with colostomy: a pooled analysis of two probiotic trials (Probio-SK-003 and Probio-SK-005) led by Slovak Cooperative Oncology Group.
- Author
-
Mego M, Kasperova B, Chovanec J, Danis R, Reckova M, Bystricky B, Konkolovsky P, Jurisova S, Porsok S, Vaclav V, Wagnerova M, Stresko M, Brezinova B, Sutekova D, Ciernikova S, Svetlovska D, and Drgona L
- Abstract
Background: Probiotics could decrease irinotecan-induced diarrhea due to the reduction of intestinal beta-d-glucuronidase activity. This study included a combined analysis of two clinical trials aimed to determine the effectiveness of the probiotics in the prophylaxis of irinotecan-induced diarrhea in metastatic colorectal cancer (CRC) patients., Methods: This combined analysis included 46 patients with CRC enrolled in the Probio-SK-003 (NCT01410955) and 233 patients from Probio-SK-005 (NCT02819960) starting a new line of irinotecan-based therapy with identical eligibility criteria. Patients were randomized in a ratio 1:1 to probiotic formulas vs. placebo administered for 12 and 6 weeks, respectively. Due to the different durations of study treatments, only the first 6 weeks of therapy were used for analysis., Results: In total, 279 patients were randomized, including 142 patients in the placebo and 137 participants in the probiotic arm. Administration of probiotics did not significantly reduce the incidence of grade 3/4 diarrhea compared to placebo (placebo 12.7% vs. probiotics 6.6%, p = 0.11). Neither the overall incidence of diarrhea (placebo 48.6% vs. probiotics 41.6%, p = 0.28) nor the incidence of enterocolitis (placebo 4.2% vs. probiotics 0.7%, p = 0.12) was different in the placebo vs. probiotic arm. However, subgroup analysis revealed that patients with a colostomy who received a placebo had a significantly higher incidence of any diarrhea (placebo 51.2% vs. probiotics 25.7%, p = 0.028) and grade 3/4 diarrhea (placebo 14.6% vs. probiotics 0.0%, p = 0.03) compared to the probiotic arm., Conclusions: This combined analysis suggests that probiotics could be beneficial in the prevention of irinotecan-induced diarrhea in colorectal cancer patients with colostomy., Competing Interests: RD is employed by S&D Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Mego, Kasperova, Chovanec, Danis, Reckova, Bystricky, Konkolovsky, Jurisova, Porsok, Vaclav, Wagnerova, Stresko, Brezinova, Sutekova, Ciernikova, Svetlovska and Drgona.)
- Published
- 2024
- Full Text
- View/download PDF
17. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
- Author
-
Orszaghova Z, Galikova D, Lesko P, Obertova J, Rejlekova K, Sycova-Mila Z, Palacka P, Kalavska K, Svetlovska D, Mladosievicova B, Mardiak J, Mego M, and Chovanec M
- Subjects
- Humans, Male, Adult, Surveys and Questionnaires, Prospective Studies, Young Adult, Middle Aged, Slovakia epidemiology, Antineoplastic Agents adverse effects, Follow-Up Studies, Adolescent, Quality of Life, Testicular Neoplasms drug therapy, Testicular Neoplasms psychology, Peripheral Nervous System Diseases chemically induced, Peripheral Nervous System Diseases psychology, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal psychology, Cancer Survivors psychology
- Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) after curative treatment for testicular germ cell tumors (GCTs) has been previously reported. It has been shown that CIPN can contribute to impaired quality of life (QOL) in cancer survivors. Herein, we aimed to evaluate CIPN in association with QOL in GCT survivors., Patients and Methods: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life - Chemotherapy-Induced Peripheral Neuropathy questionnaire (QLQ-CIPN20) and Quality of Life Questionnaire (QLQ-C30) were prospectively completed by GCT survivors (N = 151) at National Cancer Institute in Slovakia during their annual follow-up. The median follow-up was 10 years (range 4-30). Upon obtaining the scores from each questionnaire, each score from QLQ-C30 was correlated with CIPN defined as high or low (above and below median) as obtained from CIPN20., Results: GCT survivors with high overall CIPN score reported impaired QOL in QLQ-C30. The global health status was lower in survivors with high CIPN versus low CIPN (mean score ± SEM: 67.17 ± 2.00 vs. 86.18 ± 1.76, P < .00001). Survivors with high CIPN reported worse physical, role, emotional, cognitive, and social functioning compared to survivors with low CIPN (all P < .00001). CIPN high survivors perceived more fatigue, nausea, pain, dyspnea, sleeping disorders, and appetite loss compared to CIPN low survivors (all P < .004). Higher burden of CIPN was associated with more financial problems vs CIPN low (mean score ± SEM: 19.70 ± 2.64 vs. 6.67 ± 2.32, P = .00025). Spearman analysis has confirmed negative correlation of overall CIPN20 score with QLQ-C30 global health status (R = -0.53, P < .0001)., Conclusion: CIPN is a strong predictor of impairment in QOL among GCT survivors. Molecular mechanisms of neurotoxicity should be intensively studied to find preventive and therapeutic strategies., Competing Interests: Disclosure The authors declare no conflict of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12 ® Lactobacillus rhamnosus LGG ® in colorectal cancer patients.
- Author
-
Mego M, Danis R, Chovanec J, Jurisova S, Bystricky B, Porsok S, Konkolovsky P, Vaclav V, Wagnerova M, Streško M, Brezinova B, Rečková M, Sutekova D, Pazderova N, Novisedlakova M, Zomborska E, Ciernikova S, Svetlovska D, and Drgona L
- Abstract
Background: The incidence of irinotecan-induced diarrhea varies between 60-90%, by which the incidence of severe diarrhea is 20-40%. The objective of this phase III trial was to determine the effectiveness of the probiotic mixture containing Bifidobacterium , BB-12
® and Lactobacillus rhamnosus , LGG® in the prophylaxis of irinotecan-induced diarrhea in metastatic colorectal cancer patients due to a reduction in the activity of intestinal beta-D-glucuronidase., Methods: From March 2016 to May 2022, a total of 242 patients with colorectal cancer starting a new line of irinotecan-based therapy were registered to the study in 11 cancer centers in Slovakia. Patients were randomized in a ratio 1:1 to probiotic formula vs. placebo that was administered for 6 weeks. Each capsule of Probio-Tec® BG-Vcap-6.5 contained 2.7x109 colony-forming units (CFU) of 2 lyophilized probiotic strains Bifidobacterium , BB-12® (50%) and Lactobacillus rhamnosus GG, LGG® (50%)., Results: Administration of probiotics compared to placebo was not associated with a significant reduction of grade 3/4 diarrhea (placebo arm 11.8% vs. probiotic arm 7.9%, p=0.38). Neither the overall incidence of diarrhea (46.2% vs. 41.2%, p=0.51) nor the incidence of enterocolitis (3.4% vs. 0.9%, p=0.37) was different in the placebo vs. probiotic arm. Subgroup analysis revealed that patients with colostomy had higher incidence of any diarrhea and grade 3/4 diarrhea in the placebo arm compared to the probiotic arm (48.5% vs. 22.2%, p=0.06 and 15.2% vs. 0%, p=0.06, respectively). Moreover, patients on probiotic arm had significantly better diarrhea-free survival (HR = 0.41, 95%CI 0.18 - 0.95, p=0.05) and needed less loperamide (p=0.01) compared to patients on placebo arm. We did not observe any infection caused by probiotic strains used in this study., Conclusion: This study failed to achieve its primary endpoint, and results suggest a lack of benefit of administered probiotic formula for the prevention of irinotecan-induced diarrhea. However, subgroup analysis suggests a possible benefit in patients with colostomy., Competing Interests: Author RD was employed by the company S&D Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Mego, Danis, Chovanec, Jurisova, Bystricky, Porsok, Konkolovsky, Vaclav, Wagnerova, Streško, Brezinova, Rečková, Sutekova, Pazderova, Novisedlakova, Zomborska, Ciernikova, Svetlovska and Drgona.)- Published
- 2023
- Full Text
- View/download PDF
19. Cognitive impairment and biomarkers of gut microbial translocation in testicular germ cell tumor survivors.
- Author
-
Chovanec M, Kalavska K, Obertova J, Palacka P, Rejlekova K, Sycova-Mila Z, Orszaghova Z, Lesko P, De Angelis V, Vasilkova L, Svetlovska D, Mladosievicova B, Mardiak J, Pastorek M, Vlkova B, Celec P, and Mego M
- Abstract
Background: Survivors of testicular germ cell tumors (GCT) may suffer from late cognitive impairment. We hypothesized that disruption of intestinal barrier during chemotherapy and/or radiotherapy may be a contributing factor of cognitive dysfunction within the gut-blood-brain axis., Methods: GCT survivors (N = 142) from National Cancer Institute of Slovakia completed the Functional Assessment of Cancer Therapy Cognitive Function questionnaires during their annual follow-up visit at 9-year median (range 4-32). Biomarkers of gut microbial translocation and dysbiosis high mobility group box-1 (HMGB-1), lipopolysaccharide, d-lactate and sCD14 were measured from peripheral blood obtained during the same visit. Each questionnaire score was correlated with biomarkers. Survivors were treated with orchiectomy only (N = 17), cisplatin-based chemotherapy (N = 108), radiotherapy to the retroperitoneum (N = 11) or both (N = 6)., Results: GCT survivors with higher sCD14 (above median) had worse cognitive function perceived by others (CogOth domain) (mean ± SEM; 14.6 ± 0.25 vs 15.4 ± 0.25, p = 0.019), lower perceived cognitive abilities (CogPCA domain) (20.0 ± 0.74 vs 23.4 ± 0.73, p = 0.025) and lower overall cognitive function score (109.2 ± 0.74 vs 116.7 ± 1.90, p = 0.021). There were no significant cognitive declines associated with HMGB-1, d-lactate and lipopolysaccharide. Survivors treated with ≥ 400mg/m2 vs < 400mg/m2 of cisplatin-based chemotherapy had a higher lipopolysaccharide (567.8 μg/L ± 42.7 vs 462.9 μg/L ± 51.9, (p = 0.03)., Conclusions: sCD14 is a marker of monocytic activation by lipopolysaccharide and may also serve as a promising biomarker of cognitive impairment in long-term cancer survivors. While chemotherapy and radiotherapy-induced intestinal injury may be the underlying mechanism, further research using animal models and larger patient cohorts are needed to explore the pathogenesis of cognitive impairment in GCT survivors within the gut-brain axis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Chovanec, Kalavska, Obertova, Palacka, Rejlekova, Sycova-Mila, Orszaghova, Lesko, De Angelis, Vasilkova, Svetlovska, Mladosievicova, Mardiak, Pastorek, Vlkova, Celec and Mego.)
- Published
- 2023
- Full Text
- View/download PDF
20. Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors.
- Author
-
Hapakova N, Chovanec M, Rejlekova K, Kalavska K, Obertova J, Palacka P, De Angelis V, Svetlovska D, Sycova-Mila Z, Mardiak J, and Mego M
- Abstract
Testicular germ cell tumors (GCTs) are the most common solid malignancy in males aged 15-35 years. Febrile neutropenia (FN) is a serious complication of chemotherapy that frequently occurs in patients with GCTs. The present retrospective study aimed to evaluate the effect of primary granulocyte-colony stimulating factor (G-CSF) prophylaxis on the incidence of FN in patients with GCTs. The present study included a review of the medical records of patients diagnosed with GCTs treated with first-line/adjuvant chemotherapy between January 2000 and December 2017 at the National Cancer Institute (Bratislava, Slovakia). In January 2006, a decision was made to administer G-CSF prophylaxis (filgrastim or pegfilgrastim) to patients after every cycle of chemotherapy. The present study included 385 patients, and out of these, 264 patients received primary G-CSF prophylaxis, while 121 patients did not. A total of 71 patients (18.4%) suffered from FN events. In the subgroup that did not receive primary prophylaxis, 42 patients exhibited FN, while only 29 patients with primary prophylaxis suffered from FN (34.7 vs. 11.0%; P=0.00000003). According to the subgroup analysis, FN incidence was decreased in all groups that received primary prophylaxis, except for patients with stage I GCT receiving adjuvant chemotherapy, without affecting overall survival. Primary G-CSF prophylaxis was associated with markedly reduced FN incidence in patients treated with first-line chemotherapy for metastatic disease. Therefore, the results of the present study suggested that primary G-CSF prophylaxis should be considered in patients with GCT receiving first-line chemotherapy., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Hapakova et al.)
- Published
- 2022
- Full Text
- View/download PDF
21. Detection of Specific Immune Cell Subpopulation Changes Associated with Systemic Immune Inflammation-Index Level in Germ Cell Tumors.
- Author
-
Kalavska K, Sestakova Z, Mlcakova A, Gronesova P, Miskovska V, Rejlekova K, Svetlovska D, Sycova-Mila Z, Obertova J, Palacka P, Mardiak J, Chovanec M, Chovanec M, and Mego M
- Abstract
The tumor microenvironment (TME) and the host inflammatory response are closely interconnected. The interplay between systemic inflammation and the local immune response may influence tumor development and progression in various types of cancer. The systemic immune-inflammation index (SII) represents a prognostic marker for germ cell tumors (GCTs). The aim of the present study was to detect specific immune cell subpopulation changes which were associated with the SII level in chemotherapy-naïve GCT patients. In total, 51 GCT patients, prior to cisplatin-based chemotherapy, were included in the present study. Immunophenotyping of peripheral blood leukocyte subpopulations was performed using flow cytometry. The SII level was correlated with the percentage of various leukocyte subpopulations. The obtained results demonstrated that SII levels above the cut-off value of SII ≥ 1003 were associated with higher neutrophil percentages. An inverse correlation was found between the SII and the peripheral lymphocyte percentage that logically reflects the calculations of the SII index. Furthermore, the presented data also showed that in the lymphocyte subpopulation, the association with the SII was driven by T-cell subpopulations. In innate immunity-cell subpopulations, we observed a correlation between SII level and neutrophils as well as associations with eosinophil, basophil, natural killer cell and dendritic cell percentages. We suppose that the described interactions represent a manifestation of cancer-induced immune suppression. The results of the present study contribute to the elucidation of the interrelationship between tumor cells and the innate/adaptive immune system of the host.
- Published
- 2022
- Full Text
- View/download PDF
22. Comprehensive Assessment of Selected Immune Cell Subpopulations Changes in Chemotherapy-Naïve Germ Cell Tumor Patients.
- Author
-
Kalavska K, Sestakova Z, Mlcakova A, Gronesova P, Miskovska V, Rejlekova K, Svetlovska D, Sycova-Mila Z, Obertova J, Palacka P, Mardiak J, Chovanec M, Chovanec M, and Mego M
- Abstract
The pattern of immune cell distribution in testicular germ cell tumors (GCT) significantly differs from the immune environment in normal testicular tissues. The present study aimed to evaluate the role of different leukocyte subpopulation in GCTs. A cohort of 84 chemotherapy-naïve GCT patients was analyzed. Immunophenotyping of peripheral blood leukocyte subpopulations was carried out by flow cytometry. In addition, the data assessing the immunophenotypes and the baseline clinicopathological characteristics of the included subjects were statistically evaluated. Their prognostic value for the assessment of progression-free survival (PFS) and overall survival (OS) was estimated. The percentage of different innate/adaptive immune cell subpopulations was significantly associated with poor risk-related clinical features, including the number of metastatic sites, presence of retroperitoneal, mediastinal, lung, brain and non-pulmonary visceral metastases as well as with the S-stage and International Germ Cell Consensus Classification Group (IGCCCG) risk groups. In univariate analysis, the percentages of neutrophils, eosinophils, dendritic cells type 2, lymphocytes and T cytotoxic cells were significantly associated with PFS, while the neutrophil, non-classical monocyte and lymphocyte percentage were associated with OS. However, all these outcome correlations were not independent of IGCCCG in multivariate analysis. The data indicated a link among different innate/adaptive peripheral immune cell subpopulations in GCT patients. In addition, the association between these subpopulations and tumor characteristics was also investigated. The findings of the present study may contribute to a deeper understanding of the interactions between cancer and innate/adaptive immune response in GCT patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Kalavska, Sestakova, Mlcakova, Gronesova, Miskovska, Rejlekova, Svetlovska, Sycova-Mila, Obertova, Palacka, Mardiak, Chovanec, Chovanec and Mego.)
- Published
- 2022
- Full Text
- View/download PDF
23. Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial.
- Author
-
Mego M, Rejlekova K, Svetlovska D, Miskovska V, Gillis AJM, De Angelis V, Kalavska K, Obertova J, Palacka P, Reckova M, Sycova-Mila Z, Pindak D, Chovanec M, Looijenga LHJ, and Mardiak J
- Abstract
Background: Germ cell tumors represent highly curable disease even in metastatic stage. However, poor-risk patients with an unfavorable serum tumor marker (STM) decline after the first cycle of chemotherapy represent a subgroup with dismal prognosis, with approximately 50% cure rate using bleomycin, etoposide, and cisplatin (BEP)., Objective: The aim of this study was to determine the efficacy and safety of paclitaxel, ifosfamide, and cisplatin (TIP) in this patient population., Design Setting and Participants: This was an open-labeled, nonrandomized, single-center phase II trial to study the efficacy and toxicity of TIP in the first-line treatment of germ cell tumor patients with an unfavorable decline of STMs. Nineteen patients with a poor prognosis according to the International Germ Cell Cancer Collaboration Group classification and an unfavorable STM decline after the first cycle of chemotherapy were included in this phase II study (NCT02414685). The treatment regimen consisted of paclitaxel 250 mg/m
2 on day 1, ifosfamide 1200 mg/m2 on days 1-5, and cisplatin 20 mg/m2 on days 1-5, totally for four cycles., Outcome Measurements and Statistical Analysis: The primary endpoint was complete response (CR) rate. An optimal Simon two-stage design was used with a type I error of 5% and study power of 80%. If fewer than six CRs to study therapy have been observed among the first 19 patients, the study was to be terminated., Results and Limitations: A CR was achieved in four (21.1%) patients; therefore, the study was terminated in the first stage. A favorable response rate (CR or partial remission with negative tumor markers) was observed in 14 (78.9%) patients. At a median follow-up period of 35.2 mo (range, 5.6-62.1 mo), ten (52.6%) patients experienced disease progression and eight patients (42.1%) died. The 2-yr progression-free and overall survival was 41.2% (95% confidence interval [CI] 16.8-65.7) and 72.7% (95% CI 48.9-96.4), respectively. TIP was well tolerated, and no unexpected toxicity was observed. No informative biomarkers, including miR-371a-3p was identified., Conclusions: Treatment modification from the BEP to the TIP regimen in patients with an unfavorable STM decline after the first cycle of chemotherapy was not associated with improved outcome, and four cycles of BEP remain the standard treatment option in this patient population., Patient Summary: Poor-risk patients with an unfavorable serum tumor marker decline after the first cycle of chemotherapy represent a subgroup with dismal prognosis, with an approximately 50% cure rate using bleomycin, etoposide, and cisplatin (BEP). Treatment modification from the BEP regimen to the paclitaxel, ifosfamide, and cisplatin regimen in patients with an unfavorable serum tumor marker decline after the first cycle of chemotherapy was not associated with improved outcome, and four cycles of BEP remain the standard treatment option in this patient population., (© 2021 The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
24. Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients?
- Author
-
Kalavska K, Sestakova Z, Mlcakova A, Kozics K, Gronesova P, Hurbanova L, Miskovska V, Rejlekova K, Svetlovska D, Sycova-Mila Z, Obertova J, Palacka P, Mardiak J, Chovanec M, Chovanec M, and Mego M
- Subjects
- Adult, Antineoplastic Agents therapeutic use, Biomarkers, Tumor immunology, Cell Line, Tumor, Cisplatin therapeutic use, Drug Resistance, Neoplasm, Humans, Leukocytes, Mononuclear classification, Male, Middle Aged, Testicular Neoplasms drug therapy, Testicular Neoplasms genetics, Testicular Neoplasms pathology, DNA Damage, Leukocytes, Mononuclear immunology, Testicular Neoplasms immunology, Tumor Microenvironment immunology
- Abstract
Chemoresistance of germ cell tumors (GCTs) represents an intensively studied property of GCTs that is the result of a complicated multifactorial process. One of the driving factors in this process is the tumor microenvironment (TME). Intensive crosstalk between the DNA damage/DNA repair pathways and the TME has already been reported. This study aimed at evaluating the interplay between the immune TME and endogenous DNA damage levels in GCT patients. A cocultivation system consisting of peripheral blood mononuclear cells (PBMCs) from healthy donors and GCT cell lines was used in an in vitro study. The patient cohort included 74 chemotherapy-naïve GCT patients. Endogenous DNA damage levels were measured by comet assay. Immunophenotyping of leukocyte subpopulations was performed using flow cytometry. Statistical analysis included data assessing immunophenotypes, DNA damage levels and clinicopathological characteristics of enrolled patients. The DNA damage level in PBMCs cocultivated with cisplatin (CDDP)-resistant GCT cell lines was significantly higher than in PBMCs cocultivated with their sensitive counterparts. In GCT patients, endogenous DNA damage levels above the cutoff value were independently associated with increased percentages of natural killer cells, CD16-positive dendritic cells and regulatory T cells. The crosstalk between the endogenous DNA damage level and specific changes in the immune TME reflected in the blood of GCT patients was revealed. The obtained data contribute to a deeper understanding of ongoing interactions in the TME of GCTs.
- Published
- 2021
- Full Text
- View/download PDF
25. Plasma thiobarbituric acid reactive substances predicts survival in chemotherapy naïve patients with metastatic urothelial carcinoma.
- Author
-
Slopovsky J, Kucharska J, Obertova J, Mego M, Kalavska K, Cingelova S, Svetlovska D, Gvozdjakova A, Furka S, and Palacka P
- Abstract
Oxidative stress plays a significant role in development and progression of cancer, including urothelial carcinomas. TBARS (Thiobarbituric acid reactive substances) represents a marker of oxidative stress increased in various diseases. In this prospective study, we tested the hypothesis of plasma TBARS concentration and correlation with survival in chemotherapy naïve MUC (metastatic urothelial carcinoma) patients. Most of subjects (N = 65) were treated with gemcitabine and cisplatin (GC) chemotherapy. Performance status ECOG ≥2 had 11 patients, visceral metastases were present in 43. Based upon the mean of plasma TBARS, subjects were dichotomized into low and high groups. Progression-free survival (PFS), overall survival (OS) and their 95% CI were estimated by Kaplan-Meier method and compared by log-rank test. At median follow-up of 9.6 months, 65 patients experienced progression and 64 died. Subjects with low TBARS had significantly better PFS (HR 0.51) and OS (HR 0.44) opposed to high TBARS. Patients with low TBARS had significantly higher rate of neutropenia G4 and less liver involvement. High TBARS correlated with BMI above 30 kg/m
2 . Performance status and plasma TBARS were proven to be independent predictors of PFS and OS. In this study, high TBARS in MUC patients were associated with poor survival, likely due to more aggressive disease activity as reflected in increased liver involvement. Therefore, this biomarker could be used in clinical practice for early identification of patients with worse prognosis, better patient stratification, and treatment decision making., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
26. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
- Author
-
Sestakova Z, Kalavska K, Smolkova B, Miskovska V, Rejlekova K, Sycova-Mila Z, Palacka P, Obertova J, Holickova A, Hurbanova L, Jurkovicova D, Roska J, Goffa E, Svetlovska D, Chovanec M, Mardiak J, Mego M, and Chovanec M
- Subjects
- Adult, Cells, Cultured, Comet Assay methods, Disease Progression, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Leukocytes, Mononuclear pathology, Male, Middle Aged, Prognosis, Progression-Free Survival, Proportional Hazards Models, Risk Factors, Blood Cells pathology, DNA Damage genetics, Neoplasms, Germ Cell and Embryonal genetics, Neoplasms, Germ Cell and Embryonal pathology
- Abstract
Germ cell tumour (GCT) patients who fail to respond to chemotherapy or who relapse have a poor prognosis. Timely and accurately stratifying such patients could optimise their therapy. We identified endogenous DNA damage levels as a prognostic marker for progression-free (PFS) and overall (OS) survival in chemotherapy-naïve GCT patients. In the present study, we have extended our previous results and reviewed the prognostic power of DNA damage level in GCTs. Endogenous DNA damage levels were measured with the comet assay. Receiver operator characteristic analysis was applied to determine the optimal cut-off value and to evaluate its prognostic accuracy. PFS and OS were estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratio (HR) estimates were calculated by Cox regression analysis. A cut-off value of 6.34 provided the highest sensitivity and specificity, with area under curve values of 0.813 and 0.814 for disease progression and mortality, respectively. A % DNA in tail > 6.34 was significantly associated with shorter PFS (HR = 9.54, 95 % confidence interval [CI]: 3.43-26.55, p < 0.001) and OS (HR = 14.62, 95 % CI: 3.14-67.95, p = 0.001) by univariate analysis. The prognostic value of DNA damage measurement was confirmed by multivariate models (HR = 6.45, 95 % CI: 2.22-18.75, p = 0.001 for PFS and HR = 9.40, 95 % CI: 1.70-52.09, p = 0.010 for OS), when HR was adjusted for relevant clinical categories. The added prognostic value of DNA damage in combination with International Germ Cell Cancer Collaborative Group (IGCCCG) risk groups has been revealed. Endogenous DNA damage is an independent prognosticator for PFS and OS in GCT patients and its clinical use, particularly in combination with IGCCCG risk groups, may help in stratifying these patients., Competing Interests: Declaration of Competing Interest The authors declare no competing interests., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
27. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
- Author
-
Cierna Z, Miskovska V, Roska J, Jurkovicova D, Pulzova LB, Sestakova Z, Hurbanova L, Machalekova K, Chovanec M, Rejlekova K, Svetlovska D, Kalavska K, Kajo K, Babal P, Mardiak J, Ward TA, Mego M, and Chovanec M
- Subjects
- Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Cell Line, Tumor, DNA Damage drug effects, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Drug Resistance, Neoplasm, Endonucleases genetics, Endonucleases metabolism, Humans, Immunohistochemistry, Male, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local metabolism, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal genetics, Neoplasms, Germ Cell and Embryonal pathology, Phosphorylation, Prognosis, Testicular Neoplasms drug therapy, Testicular Neoplasms genetics, Testicular Neoplasms pathology, Xeroderma Pigmentosum Group A Protein genetics, Antineoplastic Agents pharmacology, Cisplatin pharmacology, DNA Repair genetics, Neoplasms, Germ Cell and Embryonal metabolism, Testicular Neoplasms metabolism, Xeroderma Pigmentosum Group A Protein metabolism
- Abstract
Background: Germ cell tumours (GCTs) represent a highly curable malignity as they respond well to cisplatin (CDDP)-based chemotherapy. Nevertheless, a small proportion of GCT patients relapse or do not respond to therapy. As this might be caused by an increased capacity to repair CDDP-induced DNA damage, identification of DNA repair biomarkers predicting inadequate or aberrant response to CDDP, and thus poor prognosis for GCT patients, poses a challenge. The objective of this study is to examine the expression levels of the key nucleotide excision repair (NER) factors, XPA, ERCC1 and XPF, in GCT patients and cell lines., Methods: Two hundred seven GCT patients' specimens with sufficient follow-up clinical-pathological data and pairwise combinations of CDDP-resistant and -sensitive GCT cell lines were included. Immunohistochemistry was used to detect the ERCC1, XPF and XPA protein expression levels in GCT patients' specimen and Western blot and qRT-PCR examined the protein and mRNA expression levels in GCT cell lines., Results: GCT patients with low XPA expression had significantly better overall survival than patients with high expression (hazard ratio = 0.38, 95% confidence interval: 0.12-1.23, p = 0.0228). In addition, XPA expression was increased in the non-seminomatous histological subtype, IGCCCG poor prognosis group, increasing S stage, as well as the presence of lung, liver and non-pulmonary visceral metastases. Importantly, a correlation between inadequate or aberrant CDDP response and XPA expression found in GCT patients was also seen in GCT cell lines., Conclusions: XPA expression is an additional independent prognostic biomarker for stratifying GCT patients, allowing for improvements in decision-making on treatment for those at high risk of refractoriness or relapse. In addition, it could represent a novel therapeutic target in GCTs.
- Published
- 2020
- Full Text
- View/download PDF
28. High Endogenous DNA Damage Levels Predict Hematological Toxicity in Testicular Germ Cell Tumor Patients Treated With First-Line Chemotherapy.
- Author
-
Hapakova N, Sestakova Z, Holickova A, Hurbanova L, Miskovska V, Chovanec M, Rejlekova K, Svetlovska D, Kalavska K, Obertova J, Palacka P, Sycova-Mila Z, Mardiak J, Chovanec M, and Mego M
- Subjects
- Adult, Antineoplastic Agents adverse effects, Cisplatin adverse effects, DNA Damage, Female, Granulocyte Colony-Stimulating Factor therapeutic use, Humans, Leukocyte Count, Leukocytes, Mononuclear drug effects, Lymphocyte Count, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal genetics, Testicular Neoplasms genetics, Young Adult, Antineoplastic Agents administration & dosage, Cisplatin administration & dosage, Leukocytes, Mononuclear chemistry, Neoplasms, Germ Cell and Embryonal drug therapy, Testicular Neoplasms drug therapy
- Abstract
Background: Testicular germ cell tumors (TGCTs) are an excellent example of chemosensitive disease. However, cisplatin-based chemotherapy has significant side effects, including myelosuppression. Previously, we found endogenous DNA damage level in peripheral blood mononuclear cells (PBMCs) to be an independent prognostic marker. In this study, we tested the hypothesis that patients with high endogenous DNA damage levels in PBMCs have an increased risk of developing hematological toxicity., Patients and Methods: One hundred twenty chemotherapy-naive TGCT patients treated in the National Cancer Institute and the St Elisabeth Cancer Institute in Bratislava, Slovakia, from 2012 to 2018 were enrolled. All patients received platinum-based chemotherapy with granulocyte colony stimulating factor support. On the day of starting treatment, we measured the DNA damage levels in PBMCs using the comet assay. We used the cutoff level of 5.25, a value previously reported to stratify patients on the basis of their prognosis. We monitored hematological toxicity during the first cycle of chemotherapy. The mean and standard error of the mean were calculated for all variables., Results: Patients with high DNA damage levels (>5.25) had more significant hematological toxicity with significantly lower nadir white blood cell count (P = .001), absolute neutrophil count (P = .013) and absolute lymphocyte count (ALC; P < .001). ALCs on day 0 (P = .005) and day 22 (P = .046) were also significantly lower in patients with high DNA damage levels., Conclusion: This study shows that higher endogenous DNA damage levels correlate with increased risk of hematological toxicity in TGCT patients. Hence, the DNA damage levels can be used to select patients for closer monitoring because of a higher risk of acute chemotherapy-related complications., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
29. βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
- Author
-
Chovanec M, Cierna Z, Miskovska V, Machalekova K, Kalavska K, Rejlekova K, Svetlovska D, Macak D, Spanik S, Kajo K, Babal P, Mego M, and Mardiak J
- Subjects
- Adolescent, Adult, Aged, B7-H1 Antigen metabolism, Humans, Immunohistochemistry, Lymphocytes, Tumor-Infiltrating immunology, Male, Middle Aged, Models, Biological, Neoplasm Staging, Neoplasms, Germ Cell and Embryonal immunology, Neoplasms, Germ Cell and Embryonal mortality, Prognosis, Testicular Neoplasms immunology, Testicular Neoplasms mortality, Tumor Microenvironment immunology, Wnt Signaling Pathway, Young Adult, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating metabolism, Lymphocytes, Tumor-Infiltrating pathology, Neoplasms, Germ Cell and Embryonal metabolism, Neoplasms, Germ Cell and Embryonal pathology, Testicular Neoplasms metabolism, Testicular Neoplasms pathology, beta Catenin metabolism
- Abstract
Background: WNT/βcatenin (WNTβ) pathway is activated in early stages of embryonic development. We aimed to evaluate the significance of βcatenin in germ cell tumors (GCTs) and explore associations with the inflamed environment., Methods: Surgical specimens from 247 patients were analyzed. Βcatenin expression was detected in the tumor tissue by immunohistochemistry and correlated with clinical characteristics, outcome, PD-L1 expression and systemic immune-inflammation index (SII). The Ingenuity Pathway Analysis (IPA) was used to investigate the immune-cell related effects of βcatenin and PD-L1 encoding genes., Results: βcatenin was expressed in 86.2% of GCTs. The expression in seminomas was significantly lower compared to all subtypes of non-seminoma (all P < 0.0001). A high expression (weighted histoscore > 150) was associated with primary mediastinal non-seminoma (P = 0.035), intermediate/poor risk disease (P = 0.033) and high tumor markers (P = 0.035). We observed a positive correlation with the PD-L1 in tumor and an inverse correlation with the SII. IPA uncovered relationships of CTNNB (βcatenin) and CD274 (PD-L1) genes and their effects on differentiation, proliferation and activation of lymphocyte subtypes., Conclusion: Herein, we showed that βcatenin is associated with male adult GCT characteristics as well as supressed immune environment.
- Published
- 2018
- Full Text
- View/download PDF
30. Long-Term Cognitive Functioning in Testicular Germ-Cell Tumor Survivors.
- Author
-
Chovanec M, Vasilkova L, Setteyova L, Obertova J, Palacka P, Rejlekova K, Sycova-Mila Z, Kalavska K, Svetlovska D, Cingelova S, Mladosievicova B, Mardiak J, and Mego M
- Subjects
- Adult, Aged, Cancer Survivors, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal mortality, Neoplasms, Germ Cell and Embryonal pathology, Prospective Studies, Testicular Neoplasms mortality, Testicular Neoplasms pathology, Young Adult, Cognition drug effects, Neoplasms, Germ Cell and Embryonal psychology, Testicular Neoplasms psychology
- Abstract
Background: Treatment for cancer may lead to development of cognitive difficulties in cancer survivors. This study aimed to evaluate long-term cognitive functioning (CogF) in germ-cell tumor (GCT) survivors., Subjects, Materials, and Methods: GCT survivors ( n = 155) from the National Cancer Institute of Slovakia completed the Functional Assessment of Cancer Therapy Cognitive Function at a median of 10 years of follow-up (range: 5-32). The study group consisted of survivors receiving a cisplatin-based chemotherapy, radiotherapy to the retroperitoneal lymph nodes, or both, whereas the control group included survivors treated with orchiectomy only., Results: Of the total survivors, 138 received treatment beyond orchiectomy and 17 controls had orchiectomy alone. Any treatment resulted in significantly greater cognitive difficulties on the overall cognitive function score. Treatment with radiotherapy was associated with cognitive declines in overall cognitive functioning and in subscales for perceived cognitive impairment and cognitive impairment perceived by others (both p < .05). The burden of chemotherapy plus radiotherapy or radiotherapy versus controls resulted in the impairment in all cognitive functioning domains (all p < .05). Overall long-term cognitive impairment was independent of age in the multivariable analysis., Conclusion: This prospective study shows that GCT survivors suffer from a long-term CogF impairment. These results may help guide clinicians' decisions in treatment and follow-up of GCTs., Implications for Practice: In this study, long-term survivors of germ-cell tumors have reported cognitive impairment after curative treatment with radiotherapy and chemotherapy compared with controls who had treatment with orchiectomy only. These data provide an argument against the use of adjuvant radiotherapy for stage I seminoma. Unnecessary overtreatment with chemotherapy and additional radiotherapy after chemotherapy should be avoided., Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article., (© AlphaMed Press 2018.)
- Published
- 2018
- Full Text
- View/download PDF
31. Systemic immune-inflammation index in germ-cell tumours.
- Author
-
Chovanec M, Cierna Z, Miskovska V, Machalekova K, Kalavska K, Rejlekova K, Svetlovska D, Macak D, Spanik S, Kajo K, Babal P, De Giorgi U, Mego M, and Mardiak J
- Subjects
- Adolescent, Adult, Aged, B7-H1 Antigen biosynthesis, B7-H1 Antigen immunology, Blood Platelets immunology, Blood Platelets pathology, Humans, Inflammation blood, Inflammation pathology, Kaplan-Meier Estimate, Lymphocytes immunology, Lymphocytes pathology, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating pathology, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal blood, Neoplasms, Germ Cell and Embryonal pathology, Neutrophils immunology, Neutrophils pathology, Progression-Free Survival, Regression Analysis, Retrospective Studies, Testicular Neoplasms blood, Testicular Neoplasms pathology, Young Adult, Inflammation immunology, Neoplasms, Germ Cell and Embryonal immunology, Testicular Neoplasms immunology
- Abstract
Background: We evaluated systemic immune-inflammation index (SII) and its association with patient outcome in germ-cell tumours (GCTs)., Methods: Two independent cohorts of patients were analysed; the discovery set (n=171) from a single institution and the validation set (n=181) previously included in a study evaluating PD-L1 in GCTs. The SII was calculated using platelet (P), neutrophil (N) and lymphocyte (L) counts before chemotherapy and correlated with survival using regression analyses and Kaplan-Meier method., Results: In the discovery cohort, the SII was associated with poor risk clinical features. Patients with low SII had significantly longer progression-free survival (HR=0.22, 95% CI 0.12-0.41, P<0.001) and overall survival (OS) (HR=0.16, 95% CI 0.08-0.32, P<0.001) compared to high SII. This index was independent of International Germ Cell Cancer Collaborative Group criteria in multivariable Cox regression analysis for OS and was validated in an independent cohort. When combining PD-L1 expression on tumour infiltrating lymphocytes (TILs) and SII, we identified three distinctive prognostic groups., Conclusions: High SII was associated with poor outcome in GCTs. Combination of PD-L1 positive TILs and SII could further refine prognosis in GCTs.
- Published
- 2018
- Full Text
- View/download PDF
32. Plasma Cytokines Correlated With Disease Characteristics, Progression-Free Survival, and Overall Survival in Testicular Germ-Cell Tumor Patients.
- Author
-
Svetlovska D, Miskovska V, Cholujova D, Gronesova P, Cingelova S, Chovanec M, Sycova-Mila Z, Obertova J, Palacka P, Rajec J, Kalavska K, Usakova V, Luha J, Ondrus D, Spanik S, Mardiak J, and Mego M
- Subjects
- Disease Progression, Disease-Free Survival, Humans, Immunoglobulin G administration & dosage, Immunoglobulin G therapeutic use, Male, Melphalan administration & dosage, Melphalan therapeutic use, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal blood, Neoplasms, Germ Cell and Embryonal immunology, Neoplasms, Germ Cell and Embryonal mortality, Organoplatinum Compounds therapeutic use, Prognosis, Prospective Studies, Testicular Neoplasms blood, Testicular Neoplasms immunology, Testicular Neoplasms mortality, Translational Research, Biomedical, Cytokines blood, Neoplasms, Germ Cell and Embryonal drug therapy, Organoplatinum Compounds administration & dosage, Testicular Neoplasms drug therapy
- Abstract
Background: Cytokines are the communicators of immune system and are involved in all immune responses. The aim of this study was to assess the correlation among plasma cytokines, patient and tumor characteristics, and clinical outcome in chemonaive testicular germ-cell tumor (TGCT) patients., Patients and Methods: This study included 92 metastatic chemotherapy-naive TGCT patients treated with platinum-based chemotherapy from July 2010 to March 2014. Plasma was isolated before first administration of chemotherapy, and the concentration of 51 plasma cytokines were analyzed using multiplex bead arrays., Results: At a median follow-up of 33.2 months (range, 0.1-54.8 months), 10.9% of patients experienced disease progression, and 7.6% died. Several cytokines were associated with different baseline clinicopathologic features. Elevated plasma levels of interferon (IFN)-α2, interleukin (IL)-2Rα, IL-16, hepatocyte growth factor (HGF), and monocyte chemotactic protein (MCP)-3 were significantly associated with worse progression-free survival and overall survival (OS). Moreover, elevated levels of stem-cell growth factor (SCGF)-β were also associated with worse OS. Patients with elevated levels of all 6 cytokines experienced significantly worse outcomes compared to patients who had fewer than 6 cytokines elevated (hazard ratio = 12.06; 95% confidence interval, 7.39-19.49; P = .002 for progression-free survival, and hazard ratio = 39.65; 95% confidence interval, 25.03-62.18; P < .00001 for OS, respectively). Results were independent of International Germ Cell Cancer Collaborative Group criteria., Conclusion: We found a correlation among progression free-survival, OS, and circulating cytokines in TGCT. This suggests the existence an association between plasma cytokines and baseline clinicopathologic features in TGCT. Plasma cytokines could be used for identification of high-risk patients who are candidates for new therapeutic approaches., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
33. Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
- Author
-
Kalavska K, Cierna Z, Chovanec M, Takacova M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Machalekova K, Kajo K, Spanik S, Mardiak J, Babal P, Pastorekova S, and Mego M
- Abstract
Testicular germ cell tumors (TGCTs) represent a highly curable malignancy, however a small proportion of patients fails to be cured with cisplatin-based chemotherapy. Carbonic anhydrase IX (CA IX) is upregulated by hypoxia in several cancer types and correlates with a poor prognosis. The present translational study evaluated expression and prognostic value of CA IX in TGCTs. Surgical specimens from 228 patients with TGCTs were processed by the tissue microarray method and subjected to immunohistochemistry with the M75 monoclonal antibody. CA IX expression was evaluated in tumors vs. adjacent normal testicular tissues and correlated with clinicopathological characteristics and clinical outcome. CA IX expression was detected in 62 (30.2%) of TGCTs compared to 0 (0%) of normal tissue adjacent to testicular tumor (P<0.001). The highest frequency of the CA IX expression was detected in teratoma (39.0%), followed by seminoma (22.7%), yolk sac tumor (22.2%), embryonal carcinoma (11.9%) and choriocarcinoma (7.7%). None of germ cell neoplasias in situ (GCNIS) exhibited CA IX expression. Patients without the CA IX tumor expression showed significantly better progression-free survival, but not overall survival, compared to patients with the CA IX expression [hazard ratio (HR), 0.57; 95% CI, 0.32-1.02; P=0.037 and HR, 0.58; 95% CI, 0.29-1.16; P=0.088, respectively]. There was no significant correlation between the CA IX expression and clinicopathological variables. The intratumoral CA IX expression can serve as a prognostic marker in the TGCT patients. These results suggest that activation of the hypoxia-induced pathways may be important in the treatment failure in TGCTs patients.
- Published
- 2017
- Full Text
- View/download PDF
34. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
- Author
-
Chovanec M, Cierna Z, Miskovska V, Machalekova K, Svetlovska D, Kalavska K, Rejlekova K, Spanik S, Kajo K, Babal P, Mardiak J, and Mego M
- Subjects
- Adolescent, Adult, Aged, Disease-Free Survival, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Lymphocytes, Tumor-Infiltrating metabolism, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal metabolism, Neoplasms, Germ Cell and Embryonal mortality, Prognosis, Programmed Cell Death 1 Receptor metabolism, Proportional Hazards Models, Testicular Neoplasms metabolism, Testicular Neoplasms mortality, Tissue Array Analysis, Young Adult, B7-H1 Antigen metabolism, Biomarkers, Tumor analysis, Lymphocytes, Tumor-Infiltrating immunology, Neoplasms, Germ Cell and Embryonal immunology, Testicular Neoplasms immunology
- Abstract
Purpose: Testicular germ cell tumors (TGCTs) are nearly universally curable malignancies. Nevertheless, standard cisplatin-based chemotherapy is not curative in a small subgroup of patients. Previously, we showed that PD-L1 overexpression is associated with worse prognosis in TGCTs, while tumor infiltrating lymphocytes (TILs) are prognostic in different types of cancer. This study aimed to evaluate the prognostic value of PD-1 and PD-L1 expressing TILs in TGCTs., Results: PD-L1 positive TILs were found significantly more often in seminomas (95.9% of patients) and embryonal carcinomas (91.0%) compared to yolk sac tumors (60.0%), choriocarcinomas (54.5%) or teratomas (35.7%) (All p < 0.05). TGCTs patients with high infiltration of PD-L1 positive TILs (HS ≥ 160) had significantly better progression-free survival (HR = 0.17, 95% CI 0.09 - 0.31, p = 0.0006) and overall survival (HR = 0.08, 95% CI 0.04 - 0.16, p = 0.001) opposite to patients with lower expression of PD-L1 (HS < 150). PD-1 expressing TILs were not prognostic in TGCTs., Materials and Methods: Surgical specimens from 240 patients with primary TGCTs were included into this translational study. The PD-1 and PD-L1 expression on tumor and TILs were detected by immunohistochemistry using anti-PD-1 and anti-PD-L1 monoclonal antibody. Scoring was performed semiquantitatively by weighted histoscore (HS) method., Conclusions: The prognostic value of PD-L1 expressing TILs in TGCTs was demonstrated for the first time.
- Published
- 2017
- Full Text
- View/download PDF
35. The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer.
- Author
-
Sestakova Z, Kalavska K, Hurbanova L, Jurkovicova D, Gursky J, Chovanec M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rejlekova K, Sycova-Mila Z, Cingelova S, Spanik S, Mardiak J, Chovanec M, and Mego M
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Comet Assay, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal pathology, Prognosis, Risk Factors, Young Adult, DNA Damage, Lymphocytes metabolism, Neoplasms, Germ Cell and Embryonal genetics, Neoplasms, Germ Cell and Embryonal mortality
- Abstract
Germ cell tumors (GCTs) are extraordinarily sensitive to cisplatin (CDDP)-based chemotherapy. DNA damage represents one of the most important factors contributing to toxic effects of CDDP-based chemotherapy. This study was aimed to evaluate the prognostic value of DNA damage level in peripheral blood lymphocytes (PBLs) from chemo-naïve GCT patients. PBLs isolated from 59 chemotherapy-naïve GCT patients were included into this prospective study. DNA damage levels in PBLs were evaluated by the Comet assay and scored as percentage tail DNA by the Metafer-MetaCyte analyzing software. The mean ± SEM (standard error of the mean) of endogenous DNA damage level was 5.25 ± 0.64. Patients with DNA damage levels lower than mean had significantly better progression free survival (hazard ratio [HR] = 0.19, 95% CI (0.04 - 0.96), P = 0.01) and overall survival (HR = 0.00, 95% CI (0.00 - 0.0), P < 0.001) compared to patients with DNA damage levels higher than mean. Moreover, there was significant correlation between the DNA damage level and presence of mediastinal lymph nodes metastases, IGCCCG (International Germ Cell Cancer Collaborative Group) risk group, and serum tumor markers level. These data suggest that DNA damage levels in PBLs of GCT patients may serve as an important prognostic marker early identifying patients with poor outcome.
- Published
- 2016
- Full Text
- View/download PDF
36. Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients.
- Author
-
Kalavska K, Chovanec M, Zatovicova M, Takacova M, Gronesova P, Svetlovska D, Baratova M, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Cierna Z, Kajo K, Spanik S, Babal P, Mardiak J, Pastorekova S, and Mego M
- Abstract
Despite the fact that testicular germ cell tumors (TGCTs) are one of the most chemosensitive solid tumors, a small proportion of patients fail to be cured following cisplatin-based first line chemotherapy. Upregulation of carbonic anhydrase IX (CA IX) in various solid tumors is associated with poor outcome. The current prospective study investigated the prognostic value of serum CA IX level in TGCTs. In total, 83 patients (16 non-metastatic following orchiectomy with no evidence of disease, 57 metastatic chemotherapy-naïve and 10 metastatic relapsed chemotherapy-pretreated) starting adjuvant and/or new line of chemotherapy and 35 healthy controls were enrolled in the study. Serum CA IX values were determined using an enzyme-linked immunosorbent assay, and intratumoral CA IX was analyzed by immunohistochemistry. Metastatic chemotherapy-naïve patients had significantly higher mean CA IX serum levels than healthy controls (490.6 vs. 249.6 pg/ml, P=0.005), while there was no difference in serum CA IX levels in non-metastatic or relapsed TGCT patients compared with healthy controls. There was no significant difference in the mean serum CA IX levels between different groups of patients and between the first and second cycle of chemotherapy, nor association with patients/tumor characteristics. Serum CA IX was not prognostic for progression-free survival [hazard ratio (HR)=0.81, P=0.730] or overall survival (HR=0.64, P=0.480). However, there was a significant association between intratumoral CA IX expression and serum CA IX concentration (rho=0.51, P=0.040). These results suggest that serum CA IX level correlates with tumor CA IX expression in TGCT patients, but fails to exhibit either a prognostic value or an association with patients/tumor characteristics.
- Published
- 2016
- Full Text
- View/download PDF
37. Phase II study of everolimus in refractory testicular germ cell tumors.
- Author
-
Mego M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Chovanec M, Rejlekova K, Zuzák P, Ondrus D, Spanik S, Reckova M, and Mardiak J
- Subjects
- Adult, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Neoplasms, Germ Cell and Embryonal pathology, Prognosis, Survival Rate, Testicular Neoplasms pathology, Young Adult, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm drug effects, Everolimus therapeutic use, Neoplasm Recurrence, Local drug therapy, Neoplasms, Germ Cell and Embryonal drug therapy, Salvage Therapy, Testicular Neoplasms drug therapy
- Abstract
Background: Testicular germ cell tumors (TGCTs) represent a highly curable disease; however, a small proportion of patients develop disease recurrence. Loss of the tumor-suppressor gene phosphatase and tensin homolog marks the transition from intratubular germ cell neoplasia to invasive GCT and is correlated with disease progression. Inactivation of phosphatase and tensin homolog is associated with deregulation of the PI3K/Akt pathway and increased mammalian target of rapamycin signaling. This study aimed to determine the efficacy and toxicity of a mammalian target of rapamycin inhibitor, everolimus, in patients with refractory TGCTs., Methods: From December 2011 to February 2015, 15 patients with refractory GCTs were enrolled in the phase II study. All patients were pretreated with at least 2 cisplatin-based therapies; 4 tumors (26.7%) were absolutely refractory to cisplatin and 9 patients (60.0%) had visceral nonpulmonary metastases. Everolimus was administered at a dose of 10mg daily until progression or unacceptable toxicity. The primary end point was the objective response rate, according to Response Evaluation Criteria in Solid Tumors., Results: No objective response was observed, but 6 patients (40.0%) achieved 12-week progression-free survival. During a median follow-up period of 3.6 months (range: 1-35.1mo), all patients experienced disease progression and 11 patients (80.0%) died. Median progression-free survival was 1.7 months (95% CI: 1.1-4.0mo) and median overall survival was 3.6 months (95% CI: 2.0-11.0mo)., Conclusions: This study failed to achieve its primary end point and our data suggest limited efficacy of everolimus against unselected heavily pretreated refractory TGCTs., Condensed Abstract: Everolimus showed limited efficacy in unselected heavily pretreated refractory TGCTs. Prolonged disease stabilization could be achieved in selected patients., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
38. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.
- Author
-
Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, Lagin A, Svetlovska D, Spanik S, Zajac V, Mardiak J, and Drgona L
- Subjects
- Aged, Aged, 80 and over, Camptothecin adverse effects, Diarrhea drug therapy, Double-Blind Method, Female, Humans, Irinotecan, Male, Middle Aged, Pilot Projects, Camptothecin analogs & derivatives, Diarrhea chemically induced, Diarrhea prevention & control, Probiotics therapeutic use
- Abstract
Purpose: Diarrhea is one of the dose limiting toxicity of irinotecan. SN-38 is main irinotecan metabolite responsible for diarrhea development, which is excreted in glucuronidated form into the intestine. This study aimed to determine the effectiveness of the probiotics in the prevention of irinotecan induced diarrhea due to reduction of intestinal beta-d-glucuronidase activity., Methods: Between January 2011 and December 2013, 46 patients with colorectal cancer starting a new line of irinotecan based therapy were included. Patients were randomized 1:1 to probiotics (PRO) or placebo (PLA). Probiotic formula Colon Dophilus™, was administered at a dose of 10×10(9)CFU of bacteria tid, orally for 12 weeks of chemotherapy. The study was prematurely terminated due to slow accrual, when 46 of 220 planned patients were accrued., Results: Twenty-three patients were randomized to PRO and 23 patients to PLA. Administration of probiotics compared to placebo led to a reduction in the incidence of severe diarrhea of grade 3 or 4 (0% for PRO vs. 17.4% for PLA, p=0.11), as well as reduction of the overall incidence of diarrhea (39.1% for PRO vs. 60.9% for PLA, p=0.24) and incidence of enterocolitis (0% for PRO vs. 8.7% for PLA). Patients on PRO used less antidiarrheal drugs compared to PLA. There was no infection caused by probiotic strains recorded., Conclusions: Administration of probiotics in patients with colorectal cancer treated with irinotecan-based chemotherapy is safe and could lead to a reduction in the incidence and severity of gastrointestinal toxicity., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
39. PARP expression in germ cell tumours.
- Author
-
Mego M, Cierna Z, Svetlovska D, Macak D, Machalekova K, Miskovska V, Chovanec M, Usakova V, Obertova J, Babal P, and Mardiak J
- Subjects
- Biomarkers, Tumor metabolism, Carcinoma, Embryonal enzymology, Carcinoma, Embryonal mortality, Carcinoma, Embryonal secondary, Choriocarcinoma enzymology, Choriocarcinoma mortality, Choriocarcinoma secondary, Endodermal Sinus Tumor enzymology, Endodermal Sinus Tumor mortality, Endodermal Sinus Tumor secondary, Humans, Immunohistochemistry methods, Lymph Nodes pathology, Lymphatic Metastasis, Male, Neoplasms, Germ Cell and Embryonal mortality, Neoplasms, Germ Cell and Embryonal secondary, Pilot Projects, Retrospective Studies, Seminoma enzymology, Seminoma mortality, Seminoma secondary, Slovakia epidemiology, Survival Rate, Testicular Neoplasms mortality, Testicular Neoplasms pathology, Testis enzymology, Testis pathology, Tissue Array Analysis, Neoplasms, Germ Cell and Embryonal enzymology, Poly(ADP-ribose) Polymerases metabolism, Testicular Neoplasms enzymology
- Abstract
Background: Poly(ADP-ribose)polymerase (PARP) inhibitors represent a new class of promising drugs in anticancer therapy., Aims: To evaluate PARP expression in testicular germ cell tumours (GCTs) and to correlate expression patterns with clinicopathological variables., Methods: In this translational study, tumour specimens from 124 patients with GCTs (114 patients with testicular primary tumours and 10 with extragonadal GCTs) were identified. PARP expression was detected by immunohistochemistry using monoclonal antibodies, scored by the multiplicative quickscore (QS) method and compared to PARP expression in normal testicular tissue., Results: We observed higher expression of PARP in testicular tumours compared to normal testicular tissue (mean QS=10.04 vs 3.31, p<0.0000001). Mean QS±SD for each histological subtype was as follows: intratubular germ cell neoplasia unclassified (IGCNU)=18.00±0.00, embryonal carcinoma=9.62±5.64, seminoma=9.74±6.51, yolk sac tumour=7.8±7.20, teratoma=5.87±5.34, and choriocarcinoma=4.50±8.33. The PARP overexpression (QS>9) was most often detected in IGCNU (100% of specimen with PARP overexpression), seminona (52.6%), embryonal carcinoma (47.0%), yolk sac tumour (33.3%), teratoma (26.7%) and choriocarcinoma (25.0%), compared to 1.9% of normal testicular tissue specimens. There was no association between PARP expression and clinical variables., Conclusions: In this pilot study, we showed for the first time, that PARP is overexpressed in testicular germ cell tumours compared to normal testis.
- Published
- 2013
- Full Text
- View/download PDF
40. Sunitinib in patients with cisplatin-refractory germ cell tumors.
- Author
-
Reckova M, Mego M, Sycova-Mila Z, Obertova J, Svetlovska D, and Mardiak J
- Subjects
- Adult, Chronic Disease, Female, Humans, Male, Middle Aged, Slovakia, Sunitinib, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cisplatin administration & dosage, Indoles administration & dosage, Neoplasms, Germ Cell and Embryonal drug therapy, Pyrroles administration & dosage
- Published
- 2012
- Full Text
- View/download PDF
41. Trastuzumab in the adjuvant treatment of breast cancer.
- Author
-
Svetlovska D, Mardiak J, and Kristova V
- Subjects
- Antibodies, Monoclonal, Humanized, Chemotherapy, Adjuvant, Female, Humans, Receptor, ErbB-2, Trastuzumab, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy
- Abstract
Four large randomized trials to assess efficacy and toxicity of trastuzumab in adjuvant systemic therapy of breast cancer have been initiated. Results clearly demonstrate, that adjuvant treatment of trastuzumab significantly improves outcomes for women with HER2 positive breast cancer. The clinically most significant adverse events of trastuzumab are serious-infusion related reactions and cardiotoxicity. Benefit for patient should be considered according to advantage versus risk (Tab. 1, Fig. 2, Ref. 17) Full Text (Free, PDF) www.bmj.sk.
- Published
- 2007
42. Treatment strategy of early-stage breast cancer.
- Author
-
Svetlovska D and Mardiak J
- Subjects
- Combined Modality Therapy, Female, Humans, Neoplasm Recurrence, Local, Breast Neoplasms therapy
- Abstract
The treatment options for early stage breast cancer include local-regional and systemic therapy. Surgery and radiotherapy can minimize the risk of local recurrence, while systemic adjuvant chemotherapy and hormonal treatment is related to prolongation of survival rate. Several prognostic factors were identified. The dominant prognostic factor is lymph node involvement with cancer. The decision regarding treatment must be made according to risk versus benefit for every patient. The absolute benefit of systemic treatment is major in patients with intermediate and poor prognosis (Tab. 3, Fig. 2, Ref. 10).
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.